Institutional members access full text with Ovid®

Share this article on:

Correlation of Serum IL-2, IL-6 and IL-10 Levels With International Prognostic Index in Patients With Aggressive Non-Hodgkin's Lymphoma.

Aydin, Fazil M.D.; Yilmaz, Mustafa M.D.; Özdemir, Feyyaz M.D.; Kavgaci, Halil M.D.; Yavuz, Melek Nur M.D.; Yavuz, Ali Aydin M.D.

American Journal of Clinical Oncology: December 2002 - Volume 25 - Issue 6 - pp 570-572
Article

Cytokines play important roles in the pathogenesis of lymphomas. The aim of this study was to determine the relations between serum levels of interleukin-2 (IL-2), IL-6, and IL-10 and parameters of International Prognostic Index (IPI). Serum levels of IL-2, IL-6, and IL-10 were measured using a sensitive enzyme-linked immunosorbent assay in the pretreatment frozen sera from 43 patients with non-Hodgkin's lymphoma. The patients we included in the study were divided into two groups, one with high risk and the other with low risk according to the IPI in regard to their ages, stages, performance status, extranodal involvements, and serum levels of lactate dehydrogenase. In the high-risk group, serum levels of IL-2 (0.852 ± 0.268 ng/ml), IL-6 (0.461 ± 0.206 ng/ml), and IL-10 (0.816 ± 0.240 ng/ml) were found to be higher than serum levels of IL-2 (0.667 ± 0.170 ng/ml), IL-6 (0.355 ± 0.075 ng/ml), and IL-10 (0.643+0.177 ng/ml) in the low-risk group (p < 0.05). There was a correlation between the patients with high risk according to the IPI criteria and high levels of serum cytokines (IL-2, IL-6, IL-10). Knowledge of the serum levels of these cytokines in patients with newly diagnosed aggressive non-Hodgkin's lymphoma may help us to have some information about the possible prognosis, the activation of disease, and to decide on appropriate therapeutic approaches for individual patients.

From the Departments of Medical Oncology (F.A., M.Y., F.Ö., H.K.) and Radiation Oncology (M.N.Y., A.A.Y.), Karadeniz Technical University School of Medicine, Trabzon, Turkey.

Address correspondence and reprint requests to Dr. Fazil Aydin, Department of Medical Oncology, Karadeniz Technical University School of Medicine, 61080 Trabzon, Turkey.

© 2002 Lippincott Williams & Wilkins, Inc.